

Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling

NCT06313398

Status	RECRUITING
Phase	Early Phase 1
Sponsor	National Heart, Lung, and Blood Institute (NHLBI)
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (8)

- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged 18 years or greater with confirmed diagnosis of SCD (all genotypes), thalassemia (beta and/or alpha), or other inherited hemoglobinopathy not otherwise specified.
- Be at steady state for their underlying disease (e.g. SCD or thalassemia) or post-bone marrow transplantation status, as evidenced by medical history.

... and 3 more (see full listing online)

Exclusion (10)

- An individual who meets any of the following criteria will be excluded from participation in this study:
- Consumption of biotin supplements or raw eggs within the last 30 days.
- Blood loss within the previous 8 weeks (>540 mL).
- Red cell transfusion for their underlying SCD and/or thalassemia within the last 3 months.
- a. Participants may be eligible after three months following their last transfusion.

... and 5 more (see full listing online)

Locations (1 total)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States